证券简称：通策医疗 证券代码：600763 编号：临 2025-022 通策医疗股份有限公司关于取消监事会的公告 通策医疗股份有限公司（以下简称"公司"）于 2025 年 8 月 22 日召开第十届监 事会第九次会议，审议通过了《关于取消监事会及免去监事职务的议案》，现将有关 事项公告如下： 根据 2024 年 7 月 1 日起实施的《中华人民共和国公司法》、《上市公司章程指 引》（2025 年修订）等相关法律法规的规定及中国证券监督管理委员会于 2024 年 12 月 27 日发布的《关于新配套制度规则实施相关过渡期安排》，结合公司的实际情况 及需求，公司不再设置监事会，免去监事张晓露先生、赵敏女士，原监事会的职权由 董事会审计委员会行使，同时废止《公司监事会议事规则》，并对《公司章程》中相 关条款做出相应修订。本次取消监事会事项不会对公司治理、生产经营产生不利影响。 本议案尚需提交公司股东大会审议。在股东大会审议通过之前，监事会及监事仍 应当按照有关法律、行政法规和《公司章程》的规定继续履行职责，确保公司的正常 运作，维护公司和全体股东利益。 公司监事会的全体监事在职期间勤勉尽责，为公司规范运作和健康发展 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by over 10% in the next six months [34]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, with a gain of 3.86% from August 8 to August 21, 2025, lagging behind the index by approximately 0.35 percentage points [13]. - All sub-sectors within the industry recorded positive returns during the same period, with the medical consumables and medical devices sectors leading with increases of 6.80% and 5.88%, respectively [14]. - Approximately 73% of stocks in the industry achieved positive returns, indicating a broad recovery across the sector [15]. - The overall price-to-earnings (PE) ratio for the SW pharmaceutical and biotechnology industry was about 54.73 times as of August 21, 2025, with a relative PE to the CSI 300 of 4.23 times, showing little change in valuation [19][28]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, gaining 3.86% from August 8 to August 21, 2025, which is 0.35 percentage points lower than the index [13]. - All sub-sectors recorded positive returns, with medical consumables and medical devices leading at 6.80% and 5.88% increases, respectively [14]. - About 73% of stocks in the industry had positive returns during this period [15]. - The industry valuation remained stable, with a PE ratio of 54.73 times and a relative PE of 4.23 times compared to the CSI 300 [19]. 2. Industry News - Significant developments include the initiation of large-scale collective procurement for high-value medical consumables, with notifications issued by Sichuan and Inner Mongolia regarding historical procurement data for cardiac occluders [26]. - The report highlights the importance of the collective procurement initiative led by Fujian province, which may have national implications for medical consumables [26]. 3. Company Announcements - Notable announcements include the approval of a new clinical trial for a drug by Teva Biopharmaceuticals, indicating ongoing innovation and development within the sector [27]. 4. Industry Outlook - The report suggests maintaining an "Overweight" rating, emphasizing the potential for recovery in previously underperforming sectors such as medical consumables and devices, especially as the industry enters a period of intensive earnings disclosures [28]. - Recommended stocks for attention include leading companies across various segments, such as Mindray Medical (300760) and Aier Eye Hospital (300015), which are expected to benefit from favorable market conditions [30].

8月21日，沪深两融数据显示，通策医疗获融资买入额0.77亿元，居两市第366位，当日融资偿还额0.79 亿元，净卖出276.83万元。 来源：金融界 融券方面，当日融券卖出0.62万股，净卖出0.60万股。 最近三个交易日，19日-21日，通策医疗分别获融资买入0.68亿元、0.73亿元、0.77亿元。 ...

证券之星消息，截至2025年8月20日收盘，通策医疗(600763)报收于46.41元，上涨1.31%，换手率 2.34%，成交量10.49万手，成交额4.84亿元。 8月20日的资金流向数据方面，主力资金净流入2909.43万元，占总成交额6.01%，游资资金净流出 726.79万元，占总成交额1.5%，散户资金净流出2182.63万元，占总成交额4.51%。 近5日资金流向一览见下表： | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-20 | 46.41 1.31% | 2909.43万 | 6.01% | -726.79万 | -1.50% | -2182.63万 | -4.51% | | 2025-08-19 | 45.81 -0.80% | -5323.34万 | -10.04% | 2071.69万 | 3.91% | 3251.65万 | 6.13% | | 2025-08-18 | 46.18 2.26% ...

Company Overview - Tongce Medical's closing price on August 20 was 46.41 yuan, with an increase of 1.31%, resulting in a rolling PE ratio of 40.53, the lowest in 16 days, and a total market value of 20.759 billion yuan [1] - The company's main business includes providing oral medical services and research, with key products being medical services, product sales, construction engineering, and comprehensive service fees [1] Financial Performance - For the first quarter of 2025, Tongce Medical reported operating revenue of 745 million yuan, a year-on-year increase of 5.11%, and a net profit of 184 million yuan, up 6.22%, with a gross profit margin of 44.21% [1] Industry Comparison - The average PE ratio for the medical services industry is 49.21, with a median of 65.65, placing Tongce Medical at the 25th position within the industry [1] - The company has a total market value of 20.759 billion yuan, compared to the industry average market value of 20.077 billion yuan and the median of 71.97 billion yuan [2]

Market Overview - On August 20, the medical services sector rose by 0.33% compared to the previous trading day, with Haocen Medical leading the gains [1] - The Shanghai Composite Index closed at 3766.21, up 1.04%, while the Shenzhen Component Index closed at 11926.74, up 0.89% [1] Top Gainers in Medical Services - Haocen Medical (002622) closed at 3.96, up 10.00% with a trading volume of 827,000 shares and a transaction value of 322 million yuan [1] - Meinian Health (002044) closed at 5.87, up 4.45% with a trading volume of 2,284,200 shares and a transaction value of 1.323 billion yuan [1] - Baicheng Pharmaceutical (301096) closed at 56.47, up 3.31% with a trading volume of 72,900 shares and a transaction value of 401 million yuan [1] Top Losers in Medical Services - Innovation Medical (002173) closed at 23.05, down 7.21% with a trading volume of 1,255,900 shares and a transaction value of 2.968 billion yuan [2] - Boji Pharmaceutical (300404) closed at 12.36, down 6.01% with a trading volume of 819,000 shares and a transaction value of 1.015 billion yuan [2] - Nanmo Biological (688265) closed at 61.50, down 5.38% with a trading volume of 32,800 shares and a transaction value of 201 million yuan [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 2.075 billion yuan from institutional investors, while retail investors saw a net inflow of 1.893 billion yuan [2][3] - The top net inflow from retail investors was in Meinian Health (002044) with 201 million yuan, despite a net outflow from institutional investors [3] - Haocen Medical (002622) had a net inflow of 114 million yuan from institutional investors, but also faced significant outflows from retail investors [3]

融券方面，当日融券卖出0.56万股，净卖出0.31万股。 来源：金融界 最近三个交易日，14日-18日，通策医疗分别获融资买入0.73亿元、0.68亿元、1.01亿元。 8月18日，沪深两融数据显示，通策医疗获融资买入额1.01亿元，居两市第352位，当日融资偿还额1.05 亿元，净卖出349.45万元。 ...

Group 1 - The core viewpoint of the news is that Tongce Medical (600763) has shown a slight increase in stock price and has reported positive financial performance for the first quarter of 2025, indicating growth in revenue and net profit [1][3]. Group 2 - As of August 15, 2025, Tongce Medical's stock closed at 45.16 yuan, up 0.38%, with a trading volume of 10.11 million shares and a transaction amount of 4.55 billion yuan [1]. - The company experienced a net outflow of main funds amounting to 27.87 million yuan, which accounted for 6.13% of the transaction amount [1]. - The latest financial report for the first quarter of 2025 shows total revenue of 745 million yuan, a year-on-year increase of 5.11%, and a net profit attributable to shareholders of 184 million yuan, up 6.22% year-on-year [1]. - The company's current ratio is 1.605, quick ratio is 1.556, and debt-to-asset ratio is 26.97% [1]. Group 3 - Tongce Medical has made investments in 12 companies and participated in 19 bidding projects, along with holding 11 administrative licenses [2].

Company Overview - Tongce Medical closed at 44.99 yuan, down 2.09%, with a rolling PE ratio of 39.29 times and a total market value of 20.124 billion yuan [1] - The company specializes in dental medical services and research, with main products including medical services, product sales, construction engineering, and comprehensive service fees [1] Financial Performance - For Q1 2025, Tongce Medical reported operating revenue of 745 million yuan, a year-on-year increase of 5.11%, and a net profit of 184 million yuan, up 6.22%, with a gross profit margin of 44.21% [1] Industry Comparison - The average PE ratio for the medical services industry is 49.00 times, with a median of 62.63 times, placing Tongce Medical at 24th in the industry ranking [1][2] - The total market value of the industry averages 20.418 billion yuan, with the median at 70.65 billion yuan [2] Institutional Holdings - As of Q1 2025, 16 institutions hold shares in Tongce Medical, all being funds, with a total holding of 11.4144 million shares valued at 471 million yuan [1]

金融界消息 截至2025年8月13日收盘，通策医疗（600763）报收于45.95元，上涨0.5%，换手率2.15%， 成交量9.64万手，成交金额4.43亿元。 天眼查商业履历信息显示，通策医疗股份有限公司，成立于1995年，位于杭州市，是一家以从事卫生为 主的企业。企业注册资本44728.9117万人民币，实缴资本32064万人民币。公司法定代表人为王毅。 通过天眼查大数据分析，通策医疗股份有限公司共对外投资了12家企业，参与招投标项目19次，此外企 业还拥有行政许可11个。 来源：金融界 资金流向方面，今日主力资金净流出1313.90万元，占比成交额2.96%。其中，超大单净流出1188.07万 元、占成交额2.68%，大单净流出125.83万元、占成交额0.28%，中单净流出流入201.56万元、占成交额 0.45%，小单净流入1112.34万元、占成交额2.51%。 通策医疗最新一期业绩显示，截至2025一季报，公司营业总收入7.45亿元、同比增长5.11%，归属净利 润1.84亿元，同比增长6.22%，扣非净利润1.82亿元，同比增长7.08%，流动比率1.605、速动比率 1.556、资产负债率 ...